BOTANIX PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 AUD | +4.76% |
|
0.00% | +15.79% |
| 03-18 | Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index | CI |
| 02-27 | Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 2.75M 1.81M 144M | Sales 2023 | 3.77M 2.48M 198M | Capitalization | 171M 112M 8.94B |
|---|---|---|---|---|---|
| Net income 2022 | -13M -8.53M -681M | Net income 2023 | -9M -5.91M -471M | EV / Sales 2022 | 17.5 x |
| Net cash position 2022 | 7.16M 4.7M 375M | Net cash position 2023 | 10.25M 6.73M 537M | EV / Sales 2023 | 42.5 x |
| P/E ratio 2022 |
-4.21
x | P/E ratio 2023 |
-16.4
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.76% | ||
| Current month | -2.22% | ||
| 1 month | -6.38% | ||
| 3 months | +29.41% | ||
| 6 months | +57.14% | ||
| Current year | +15.79% |
1 week
0.21
0.23
1 month
0.210.24
Current year
0.160.24
1 year
0.080.24
3 years
0.050.24
5 years
0.020.29
10 years
0.020.29
| Managers | Title | Age | Since |
|---|---|---|---|
Howie McKibbon
CEO | Chief Executive Officer | - | 30/04/19 |
Vincent Ippolito
CHM | Chairman | 65 | 19/05/19 |
| Chief Tech/Sci/R&D Officer | 68 | 28/02/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stewart Washer
BRD | Director/Board Member | 54 | 20/02/19 |
Henry Bosch
BRD | Director/Board Member | - | 30/06/16 |
Vincent Ippolito
CHM | Chairman | 65 | 19/05/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.22 | +4.76% | 3 268 674 |
| 26/04/24 | 0.21 | -2.33% | 1,749,101 |
| 24/04/24 | 0.215 | 0.00% | 1,530,244 |
| 23/04/24 | 0.215 | -2.27% | 2,173,258 |
| 22/04/24 | 0.22 | -2.22% | 1,501,920 |
Delayed Quote Australian S.E., April 29, 2024 at 07:10 am
More quotes
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis and acne respectively. It is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +15.79% | 216M | |
| +3.89% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- BOT Stock
